Question:
A biopharmaceutical company that relocated from Britain to the Bay State a year ago has filed plans to seek an initial public offering worth as much as $45 million.

BioVex Group Inc. of Cambridge, Mass., filed initial paperwork Tuesday outlining IPO plans. Specific terms of the pricing and timing of the offering haven't been disclosed yet, but the company in its filing says the overall offering price could be as high as $45 million. BioVex has retained the Janney Montgomery Scott Investment Banking Group as lead manager and Stifel Nicolaus as co-manager.

BioVex was founded in 1999 and moved to Massachusetts last year with a long-term goal to also build a local manufacturing site. BioVex employs more than 50 people, most of whom continue to conduct research in Oxford, England.

As of last June, BioVex had raised about $65 million in venture financing. The company's core technology uses the herpes simplex virus to create treatments to fight cancer by destroying tumor cells while leaving healthy cells untouched. The company's has two treatments in clinical trials to treat head and neck cancer and melanoma. A second product -- a traditional vaccine to prevent genital herpes -- is due to enter the clinic in 2007.

BioVex lost more than $14.2 million on roughly $22 million in revenue in its 2006 fiscal year, which ended March 31, according to paperwork the company filed with the U.S. Securities and Exchange Commission.

BioVex plans to trade on the Nasdaq exchange under the ticker symbol BVEX. The company, in its filing, said the money raised in the IPO will help fuel clinical development expenses.

Answer:
http://www.biovex.com/20_09_07.htm

complete protection in animals? kick ass.